图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-08-31,10% Owner,Chione Ltd ,卖出,11468普通股, $21.05
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-08-30,10% Owner,Chione Ltd ,卖出,200000普通股, $21.00
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-08-30,Director,Mirza Mansoor Raza ,卖出,2500普通股, $21.00
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-08-30,Director,Mirza Mansoor Raza ,期权,2500普通股, $1.92
$Karyopharm Therapeutics Inc.(KPTI)$ 8-K - Current report Filed: 2018-09-04 AccNo: 0001193125-18-265426 Size: 18 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers http...
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-08-29,Director,Mirza Mansoor Raza ,卖出,2500普通股, $20.00
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-08-29,Director,Mirza Mansoor Raza ,期权,2500普通股, $1.49
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-08-29,10% Owner,Chione Ltd ,卖出,200000普通股, $19.59
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-08-27,10% Owner,Chione Ltd ,卖出,14026普通股, $18.52
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-08-20,CEO,Kauffman Michael ,卖出,10000普通股, $17.46